RxDoctor Payments Data

Timothy Berger, MD

Dermatology · San Francisco, CANPI 1124079181

Payments from drug & device makers

$281,352in general payments, 2019–2025

Across 105 payments — averaging $2679.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$106K
  • Sanofi-aventis U.S. LLC$83K
  • Regeneron Healthcare Solutions, Inc.$63K
  • Galderma Laboratories, L.p.$13K
  • Kiniksa Pharmaceuticals International, PLC$12K
  • Regeneron$3K
  • plus $3K from 5 others
$2,524in research payments, 2019–2025

Across 1 payment — averaging $2523.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$3K

What the payments were for

  • Consulting fees$102,04838%
  • Speaking & faculty fees$123,22346%
  • Travel & lodging$41,70515%
  • Food & beverage$2,7081%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$281,352 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$39,730
Medicare patients
149
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab78$296,995
Dupixent SyringeDupilumab63$276,363
RinvoqUpadacitinib15$99,259
AdbryTralokinumab-Ldrm19$74,425
Tacrolimus46$9,790
Clobetasol Propionate64$3,181
Acitretin13$2,538
Gabapentin122$1,689
Hydroxychloroquine Sulfate63$1,666
MethotrexateMethotrexate Sodium42$1,099
Fluocinonide17$1,017
Triamcinolone Acetonide60$996
Doxycycline Hyclate23$964
Pentoxifylline15$817
Mirtazapine12$812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$118$99,25915 claims
LEO Pharma Inc.Adbry$120$74,42519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →